Category Archives: Globe Newswire

InspireMD Reports Third Quarter 2026 Financial Results

InspireMD Reports Third Quarter 2026 Financial Results

– Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market – – Company to host investor conference call today, November 12th, at 4:30pm ET – MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® […]

InspireMD Announces Proposed Public Offering

InspireMD Announces Proposed Public Offering

MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it has commenced a proposed public offering of (i) shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded […]

Methanol Market Volume to Reach 145.4 Million Tons by 2032 Driven by Petrochemical Demand & Marine Fuel Adoption – Reports Mordor Intelligence

Methanol Market Volume to Reach 145.4 Million Tons by 2032 Driven by Petrochemical Demand & Marine Fuel Adoption - Reports Mordor Intelligence

The methanol market is driven by expanding petrochemical capacity across China, the United States, and emerging Asian economies, the marine sector’s shift toward low-carbon fuels and growing adoption of green methanol, increasing use of methanol-to-olefins (MTO) routes, the expansion of waste-to-methanol projects using municipal solid waste (MSW) gasification, and rising e-methanol demand supported by CO₂-utilization […]

PRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a Hearing

PRF Technologies Receives Nasdaq Delisting Determination Regarding Minimum Bid Price Requirement and Requests a Hearing

Hearing request stays any suspension or delisting action; ordinary shares continue to trade on the Nasdaq Capital Market pending the Hearings Panel’s decision TEL AVIV, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) — PRF Technologies Ltd. (Nasdaq: PRFX) (“PRF” or the “Company”) today announced that on November 9, 2026, it received a letter from the Listing […]

YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease

YD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease

FDA agrees to provide written guidance by January 4, 2027, to support development of YDB-LMSCEV-001 TAIPEI, Taiwan, Nov. 12, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced that the U.S. Food and Drug Administration (the “FDA”) […]

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures

– Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually – – Approval supported by CGUARDIANS II pivotal trial data, which demonstrated 100% acute device success and zero death, stroke, myocardial infarction or stent thrombosis reported at 30 days – MIAMI, Nov. 12, […]

BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BIO GREEN MED SOLUTION REPORTS THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

KUALA LUMPUR, MALAYSIA, Nov. 12, 2026 (GLOBE NEWSWIRE) — Bio Green Med Solution, Inc. (NASDAQ: BGMS; “BGMS” or the “Company”), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced third quarter financial results and provided a business update. Highlights of the third quarter ended September 30, 2026, […]

Cosmetic Peptide Synthesis Market: $354.85 Mn by 2032 as Demand for Advanced Skincare Ingredients Accelerates, Reports Mordor Intelligence

Cosmetic Peptide Synthesis Market: $354.85 Mn by 2032 as Demand for Advanced Skincare Ingredients Accelerates, Reports Mordor Intelligence

The cosmetic peptide synthesis market is projected to register a CAGR of 5.34% from 2027 to 2032, with Asia-Pacific emerging as the fastest-growing regional market. Hyderabad, India, Nov. 12, 2026 (GLOBE NEWSWIRE) — The global cosmetic peptide synthesis market is projected to grow from USD 260.20 million in 2026 and USD 274 million in 2027 to […]

AgentiSend Offers a Resend Alternative for Apps, Up to 75% Cheaper, With Per-Key Send Budgets and a Kill Switch for AI Agents

AgentiSend Offers a Resend Alternative for Apps, Up to 75% Cheaper, With Per-Key Send Budgets and a Kill Switch for AI Agents

The transactional email API accepts Resend SDK requests unchanged, gives 5,000 free emails a month, and its open-source agent-email-guard cut a 400-email runaway agent loop to 3 in a published benchmark. Dubai, United Arab Emirates, Nov. 12, 2026 (GLOBE NEWSWIRE) — AgentiSend, a Resend alternative for teams that send password resets, receipts, alerts and sign-in […]

BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight

BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight

The BCMA targeted therapies competitive landscape report delivers important insights into approved as well as ongoing research on 100+ pipeline BCMA targeted therapies, clinical strategies, upcoming therapeutics, and commercial analysis. New York, USA, Nov. 12, 2026 (GLOBE NEWSWIRE) — BCMA Targeted Therapies Competitive Landscape Analysis: 100+ Pipeline Therapies Driving Innovation in Therapeutics Segment | DelveInsight  […]